SEC Filings
Iovance's October Investor Deck Repeats Its Raised 2026 Revenue Target Of $410 Million–$420 Million
The cell therapy company's refreshed presentation also cites about $304 million in cash and a runway into the second half of 2028.
IOVA
Iovance Biotherapeutics (IOVA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
